BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer

Ehmsen et al. evaluate the neutralizing capacity to current SARS-CoV-2 variants in patients with cancer before and after receiving the BNT162b2 bivalent mRNA vaccine booster. Bivalent vaccine provides some protection against BQ.1.1 but fails to protect against XBB.1 and XBB.1.5 in patients with canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ehmsen, Sidse, Pedersen, Rune M., Bang, Line L., Asmussen, Anders, Kragh, Amalie, Holm, Dorte K., Sydenham, Thomas V., Jensen, Thøger G., Jeppesen, Stefan S., Frederiksen, Henrik, Andersen, Thomas E., Ditzel, Henrik J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910012/
https://www.ncbi.nlm.nih.gov/pubmed/36804967
http://dx.doi.org/10.1016/j.ccell.2023.02.003
_version_ 1784884697606651904
author Ehmsen, Sidse
Pedersen, Rune M.
Bang, Line L.
Asmussen, Anders
Kragh, Amalie
Holm, Dorte K.
Sydenham, Thomas V.
Jensen, Thøger G.
Jeppesen, Stefan S.
Frederiksen, Henrik
Andersen, Thomas E.
Ditzel, Henrik J.
author_facet Ehmsen, Sidse
Pedersen, Rune M.
Bang, Line L.
Asmussen, Anders
Kragh, Amalie
Holm, Dorte K.
Sydenham, Thomas V.
Jensen, Thøger G.
Jeppesen, Stefan S.
Frederiksen, Henrik
Andersen, Thomas E.
Ditzel, Henrik J.
author_sort Ehmsen, Sidse
collection PubMed
description Ehmsen et al. evaluate the neutralizing capacity to current SARS-CoV-2 variants in patients with cancer before and after receiving the BNT162b2 bivalent mRNA vaccine booster. Bivalent vaccine provides some protection against BQ.1.1 but fails to protect against XBB.1 and XBB.1.5 in patients with cancer.
format Online
Article
Text
id pubmed-9910012
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-99100122023-02-09 BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer Ehmsen, Sidse Pedersen, Rune M. Bang, Line L. Asmussen, Anders Kragh, Amalie Holm, Dorte K. Sydenham, Thomas V. Jensen, Thøger G. Jeppesen, Stefan S. Frederiksen, Henrik Andersen, Thomas E. Ditzel, Henrik J. Cancer Cell Letter Ehmsen et al. evaluate the neutralizing capacity to current SARS-CoV-2 variants in patients with cancer before and after receiving the BNT162b2 bivalent mRNA vaccine booster. Bivalent vaccine provides some protection against BQ.1.1 but fails to protect against XBB.1 and XBB.1.5 in patients with cancer. Elsevier Inc. 2023-04-10 2023-02-09 /pmc/articles/PMC9910012/ /pubmed/36804967 http://dx.doi.org/10.1016/j.ccell.2023.02.003 Text en © 2023 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter
Ehmsen, Sidse
Pedersen, Rune M.
Bang, Line L.
Asmussen, Anders
Kragh, Amalie
Holm, Dorte K.
Sydenham, Thomas V.
Jensen, Thøger G.
Jeppesen, Stefan S.
Frederiksen, Henrik
Andersen, Thomas E.
Ditzel, Henrik J.
BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer
title BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer
title_full BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer
title_fullStr BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer
title_full_unstemmed BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer
title_short BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer
title_sort bq.1.1, xbb.1, and xbb.1.5 neutralization after bivalent mrna covid-19 booster in patients with cancer
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910012/
https://www.ncbi.nlm.nih.gov/pubmed/36804967
http://dx.doi.org/10.1016/j.ccell.2023.02.003
work_keys_str_mv AT ehmsensidse bq11xbb1andxbb15neutralizationafterbivalentmrnacovid19boosterinpatientswithcancer
AT pedersenrunem bq11xbb1andxbb15neutralizationafterbivalentmrnacovid19boosterinpatientswithcancer
AT banglinel bq11xbb1andxbb15neutralizationafterbivalentmrnacovid19boosterinpatientswithcancer
AT asmussenanders bq11xbb1andxbb15neutralizationafterbivalentmrnacovid19boosterinpatientswithcancer
AT kraghamalie bq11xbb1andxbb15neutralizationafterbivalentmrnacovid19boosterinpatientswithcancer
AT holmdortek bq11xbb1andxbb15neutralizationafterbivalentmrnacovid19boosterinpatientswithcancer
AT sydenhamthomasv bq11xbb1andxbb15neutralizationafterbivalentmrnacovid19boosterinpatientswithcancer
AT jensenthøgerg bq11xbb1andxbb15neutralizationafterbivalentmrnacovid19boosterinpatientswithcancer
AT jeppesenstefans bq11xbb1andxbb15neutralizationafterbivalentmrnacovid19boosterinpatientswithcancer
AT frederiksenhenrik bq11xbb1andxbb15neutralizationafterbivalentmrnacovid19boosterinpatientswithcancer
AT andersenthomase bq11xbb1andxbb15neutralizationafterbivalentmrnacovid19boosterinpatientswithcancer
AT ditzelhenrikj bq11xbb1andxbb15neutralizationafterbivalentmrnacovid19boosterinpatientswithcancer

Ejemplares similares